Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

FEMY

Femasys Inc

Apr 26 • 09:51AM ET

1.35

Dollar change +0.02
Percentage change 1.50	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	7.80%	Shs Outstand	21.66M	Perf Week	2.27%
Market Cap	29.84M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.00%	Shs Float	20.38M	Perf Month	-8.16%
Income	-14.25M	PEG	-	EPS next Q	-0.19	Inst Own	6.42%	Short Float	5.85%	Perf Quarter	67.14%
Sales	1.07M	P/S	27.88	EPS this Y	27.15%	Inst Trans	4.55%	Short Ratio	1.63	Perf Half Y	12.50%
Book/sh	0.85	P/B	1.59	EPS next Y	42.93%	ROA	-63.81%	Short Interest	1.19M	Perf Year	62.26%
Cash/sh	0.98	P/C	1.37	EPS next 5Y	-	ROE	-84.82%	52W Range	0.25 - 4.75	Perf YTD	38.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.85%	ROI	-57.81%	52W High	-71.58%	Beta	-2.79
Dividend TTM	-	Quick Ratio	7.37	Sales past 5Y	4.12%	Gross Margin	-20.16%	52W Low	444.57%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	7.59	EPS Y/Y TTM	2.85%	Oper. Margin	-1353.43%	RSI (14)	42.26	Volatility	7.73% 8.70%
Employees	32	Debt/Eq	0.37	Sales Y/Y TTM	-11.13%	Profit Margin	-1329.06%	Recom	1.00	Target Price	9.75
Option/Short	No / Yes	LT Debt/Eq	0.34	EPS Q/Q	16.97%	Payout	-	Rel Volume	0.05	Prev Close	1.33
Sales Surprise	-6.21%	EPS Surprise	5.88%	Sales Q/Q	-9.02%	Earnings	Mar 28 AMC	Avg Volume	734.00K	Price	1.35
SMA20	-7.91%	SMA50	-15.70%	SMA200	25.47%	Trades		Volume	3,775	Change	1.50%

Apr-18-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives (GlobeNewswire)
Mar-28-24 10:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.44%
04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:00AM	Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape (GlobeNewswire)
Mar-20-24 08:15AM	Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility (GlobeNewswire) -10.00%
09:00AM	Loading…
Mar-13-24 09:00AM	Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 (GlobeNewswire) -5.24%
Mar-06-24 09:00AM	Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution (GlobeNewswire) -11.27%
Feb-28-24 09:00AM	Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF (GlobeNewswire) +9.26%
Feb-06-24 08:30AM	Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer (GlobeNewswire) +13.27%
Jan-26-24 08:00AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women (GlobeNewswire)
Jan-23-24 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology (GlobeNewswire)
Dec-15-23 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine (GlobeNewswire)
Nov-30-23 08:30AM	Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 05:27PM	30 Countries with the Lowest Median Age in the World (Insider Monkey)
08:30AM	Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch (GlobeNewswire)
03:38PM	Loading…
Nov-23-23 03:38PM	20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey)
Nov-15-23 08:30AM	PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. (Business Wire) +8.60%
07:30AM	Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech (GlobeNewswire)
Nov-14-23 07:00AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update (GlobeNewswire) -10.58%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey) +20.87%
Oct-26-23 08:30AM	Femasys Inc. EU MDR Final Audit Successfully Completed (GlobeNewswire)
Oct-25-23 08:00AM	Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women's Health at the American Association of Gynecologic Laparoscopic Surgeons (GlobeNewswire)
Oct-24-23 04:13AM	Femasys (FEMY) to Report Q3 Earnings: What's in the Cards? (Zacks) +5.98%
Oct-11-23 07:00AM	Femasys Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -6.25%
Oct-04-23 08:30AM	Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine (GlobeNewswire) -8.03%
Oct-03-23 08:30AM	Femasys Inc. MDSAP Surveillance Audit Successfully Completed (GlobeNewswire) -35.99%
Oct-02-23 07:08PM	3 Micro-Cap Stocks Set to Explode Higher (InvestorPlace) +30.54%
Sep-27-23 08:00AM	Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate (GlobeNewswire) -25.00%
Sep-25-23 05:25PM	Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution (GlobeNewswire) +6.97%
Sep-20-23 08:30AM	Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control (GlobeNewswire)
08:30AM	Loading…
Sep-06-23 08:30AM	Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 08:30AM	Femasys Inc. Obtains Medical Device Establishment License from Health Canada (GlobeNewswire)
Aug-10-23 08:00AM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire) -6.50%
Aug-03-23 08:45AM	Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc (GlobeNewswire)
Jul-27-23 08:45AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control (GlobeNewswire) +130.77%
Jul-03-23 09:55AM	Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now (Zacks)
Jun-26-23 08:00AM	Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women (GlobeNewswire) +6.25%
Jun-15-23 08:00AM	Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences (GlobeNewswire) +10.87%
Jun-14-23 08:00AM	Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023 (GlobeNewswire) -5.97%
Jun-08-23 08:30AM	Femasys FemCath Intrauterine Catheter Receives Product Approval in Canada (GlobeNewswire) -9.99%
May-11-23 04:05PM	Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023 (GlobeNewswire)
08:30AM	Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting (GlobeNewswire)
May-03-23 08:30AM	Femasys FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada (GlobeNewswire)
May-01-23 04:05PM	Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology (GlobeNewswire) +6.09%
Apr-19-23 08:00AM	Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.61%
Apr-18-23 08:00AM	Femasys FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada (GlobeNewswire) +16.67%
Mar-30-23 08:00AM	Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update (GlobeNewswire)
Mar-09-23 08:00AM	Femasys Inc. to Participate in The Post-Roe Fertility Journey Panel Discussion at SXSW 2023 (GlobeNewswire) -8.80%
Dec-19-22 09:00AM	Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device (GlobeNewswire)
Dec-12-22 08:30AM	Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons (GlobeNewswire)
Nov-29-22 07:00AM	Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design (GlobeNewswire) -8.13%
Nov-21-22 08:30AM	Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-12-22 08:17AM	Femasys Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 09:55AM	Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.98%
08:44AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire)
Oct-20-22 08:00AM	Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement (GlobeNewswire)
Oct-14-22 04:05PM	Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress (GlobeNewswire)
Oct-12-22 08:00AM	Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs (GlobeNewswire) -16.15%
Oct-06-22 08:01AM	Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control (GlobeNewswire)
Sep-29-22 08:00AM	Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team (GlobeNewswire)
Sep-01-22 04:05PM	Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-10-22 05:45PM	Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Femasys To Participate in Upcoming BTIG Biotechnology Conference (GlobeNewswire) +8.81%
Jul-20-22 07:00AM	Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade (GlobeNewswire)
Jul-11-22 08:30AM	Femasys to Participate in the Womens Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET (GlobeNewswire) -6.30%
Jul-06-22 08:00AM	Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board (GlobeNewswire) +5.76%
Jun-28-22 05:31PM	2 Contraceptive Stocks That Could Benefit From Roe v. Wade Reversal (TipRanks)
Jun-15-22 08:00AM	Femasys Inc. to Present at the LSX World Congress USA 2022 (GlobeNewswire) -7.14%
May-21-22 10:19AM	Is Femasys (NASDAQ:FEMY) In A Good Position To Invest In Growth? (Simply Wall St.)
May-11-22 04:05PM	Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2022 (GlobeNewswire) -7.10%
Mar-25-22 08:00AM	Femasys Inc. to Participate in the M-Vest 2022 Virtual Growth Conference (GlobeNewswire)
Mar-24-22 04:05PM	Femasys Inc. Announces Financial Results for the Year Ended December 31, 2021 (GlobeNewswire)
Feb-24-22 08:00AM	Femasys Inc. Announces the Appointment of Dov Elefant to New Position of Chief Financial Officer (GlobeNewswire)
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures (PR Newswire)
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? (Simply Wall St.)
Jan-20-22 08:00AM	Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member (GlobeNewswire)
Dec-23-21 08:05AM	Femasys Inc. to Participate in Upcoming January Investor Conferences (GlobeNewswire)
Nov-10-21 04:05PM	Femasys Inc. Announces Financial Results for the Third Quarter of 2021 (GlobeNewswire)
Sep-23-21 05:46PM	Femasys Inc. to Present at The MedTech Conference (GlobeNewswire) +6.04%
Sep-20-21 04:05PM	Femasys Inc. To Join the Russell Microcap® Index (GlobeNewswire) -5.05%
Sep-18-21 09:31AM	Bullish insiders bet US$2.6m on Femasys Inc. (NASDAQ:FEMY) (Simply Wall St.)
Sep-01-21 04:05PM	Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer (GlobeNewswire)
Aug-11-21 04:05PM	Femasys Inc. Announces Financial Results for the Second Quarter of 2021 (GlobeNewswire)
Jul-20-21 08:31AM	Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed (GlobeNewswire) +14.74%
Jul-19-21 10:35AM	These 3 Stocks May Be Reaching a Bottom; Analysts Say Buy (TipRanks) -6.68%
Jun-21-21 08:49AM	Chardan Acts as Lead Left Bookrunner in Femasys' $34.45 Million IPO (PR Newswire) -9.58%
Jun-18-21 05:19PM	Peter Thiels Atai Life Sciences and 5 Other Companies List Shares (Barrons.com)

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FEMY

Femasys Inc

Upgrade your FINVIZ experience